Top
Begin typing your search above and press return to search.
Madhyamam
    keyboard_arrow_down
    Login
    exit_to_app
    DEEP READAll arrow_drop_down
    The ogres in the mind
    access_time 8 Sep 2020 11:27 AM GMT
    Why worry about populism?
    access_time 4 Sep 2020 9:51 AM GMT
    Media mind-set towards minorities
    access_time 15 July 2020 4:29 PM GMT
    exit_to_app
    Homechevron_rightBusinesschevron_rightPfizer to shut...

    Pfizer to shut Chennai, Aurangabad units; 1,700 workers likely to be affected

    text_fields
    bookmark_border
    Pfizer to shut Chennai, Aurangabad units; 1,700 workers likely to be affected
    cancel

    Mumbai: U.S.-based pharma major Pfizer on Wednesday said it plans to shut down its manufacturing units in Chennai and Aurangabad in the current fiscal due to very significant long-term loss of product demand. The closure is expected to impact nearly 1,700 workers.

    The company’s Irungattukottai unit in Tamil Nadu currently employs approximately 1,000 workers and Maharashtra’s Aurangabad site employs approximately 700. The exact timing of the exit of these sites is yet to be determined, the firm said.

    The recommendation to exit both the sites are the result of significant loss of product demand, making manufacturing at these sites unviable, the company said.

    “Pfizer has conducted a thorough evaluation of the IKKT (Irungattukottai) and Aurangabad sites and concluded that due to the very significant long-term loss of product demand, manufacturing at these sites is not viable.

    As a result, both sites will immediately cease manufacturing with the intention to exit as soon as possible in 2019. The exact timing of the exit is to be determined,” a Pfizer spokesperson said. Both plants are purely export-oriented sites and do not supply products for Pfizer’s India commercial operations, it said.

    Show Full Article
    TAGS:
    Next Story